Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 1, 2010

Primary Completion Date

September 13, 2011

Study Completion Date

September 13, 2011

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Beraprost Sodium Modified Release

60µg Tablets, twice a day for 12 weeks

Trial Locations (17)

7

Mater Misericordiae University Hospital Ltd., Dublin

1070

Universite Libre de Bruxelles, Bruxellas

3000

Catholic University of Leuven, Leuven

10003

Beth Israel Medical Center, New York

10461

Albert Einstein College of Medicine, The Bronx

15212

Allegheny General Hospital, Pittsburgh

50937

Klinikum der Universitat zu Koln, Cologne

60566

Edward Heart Hospital, Naperville

69120

Abt. Innere Medizin III, Medizinische Universitatsklinik, Heidelberg

75390

UT Southwestern Medical Center, Dallas

90502

Harbor-UCLA Medical Center, Torrance

700503

Institutul de Boli Cardiovasculare, Lasi

2, 128 08

General Teaching Hospital, Prague

01307

Medizinische Klinik und Poliklinik, Dresden

04103

Universitatsklinik Leipzig Abteilung Pulmologie, Leipzig

022322

Institutul de Urgenta pentru Boli, Bucharest

050159

Institutul National de Pneumologie, Bucharest

Sponsors
All Listed Sponsors
lead

Lung Biotechnology PBC

INDUSTRY

NCT00989963 - Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) | Biotech Hunter | Biotech Hunter